Risk of relapse after natalizumab withdrawal-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk of relapse after natalizumab withdrawal

Published:2016-10-28 Issue:6 Volume:3 Page:e297
ISSN:2332-7812
Container-title:Neurology - Neuroimmunology Neuroinflammation
language:en
Short-container-title:Neurol Neuroimmunol Neuroinflamm

Author:

Papeix Caroline,Vukusic Sandra,Casey Romain,Debard Nadine,Stankoff Bruno,Mrejen Serge,Uhry Zoe,Van Ganse Eric,Castot Anne,Clanet Michel,Lubetzki Catherine,Confavreux Christian,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Clinical Neurology,Neurology

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world treatment outcomes and safety of natalizumab in Finnish multiple sclerosis patients;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2023-10

2. Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis;Science Advances;2023-05-19

3. Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment;Journal of Neurology;2023-03-13

4. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis;CNS Drugs;2022-11-09

5. Use of natalizumab in persons with multiple sclerosis: 2022 update;Multiple Sclerosis and Related Disorders;2022-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP